Alexei Kharitonenkov

Title: Innovations by Alexei Kharitonenkov

Introduction

Alexei Kharitonenkov is a notable inventor based in Zionsville, Indiana. He has made significant contributions to the field of biochemistry, particularly in the optimization of peptides related to FGF21. His work has implications for understanding metabolic processes and developing therapeutic strategies.

Latest Patents

Kharitonenkov holds a patent for "FGF21 C-terminal peptide optimization." This patent discloses modified C-terminal fragments of FGF21 that are optimized for binding to Klotho β or antagonizing FGF21 activity. The modified FGF21 peptides exhibit enhanced activity at the FGF21 receptor, which could lead to advancements in metabolic disease treatments. Additionally, the patent includes conjugates formed between the optimized FGF21 peptide fragments and insulin-like peptides or nuclear hormone receptor ligands.

Career Highlights

Kharitonenkov is affiliated with Indiana University, where he conducts research and collaborates with other experts in the field. His work has garnered attention for its innovative approach to peptide optimization and its potential applications in medicine.

Collaborations

Some of Kharitonenkov's notable coworkers include Richard Dennis DiMarchi and Pengyun Li. Their collaborative efforts contribute to the advancement of research in peptide biology and therapeutic development.

Conclusion

Alexei Kharitonenkov's innovative work in peptide optimization represents a significant advancement in biochemistry. His contributions have the potential to impact therapeutic strategies for metabolic diseases.